LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi in a Series A+ financing round led by existing investors. The funds will be used to accelerate a Phase I clinical study and pre-clinical research, expand the product pipeline, and enhance the technology platform.
Company Profile
Founded in 2020, LongBio Pharma focuses on the development of autoimmune disease drugs. The company has initiated a Phase I clinical study for its Category 1 drug candidate LP-003, marking a significant milestone in its R&D efforts.
Funding Details
The Series A+ round, led by existing investors, will support LongBio’s ongoing clinical trials and pipeline expansion. The company aims to leverage the funding to strengthen its position in the autoimmune disease treatment market.-Fineline Info & Tech
